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Abstract 
 
Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic 
inflammation that affects the joints. It occurs when the immune system attacks the 
body's own tissues and organs. The precise cause of RA is not fully understood but 
evidence suggests that genes, hormones and environmental factors could be involved. 
It has been established that human leukocyte antigen (HLA) loci is a strong risk factor 
of RA. Specifically, the shared epitope (SE) region of HLA-DRB1 and variations at 
position 11 and 13 of HLA-DRB1 and position 77 of HLA-A have shown strong 
association with RA. The hypothesis of this study was that these variations could be 
associated with RA patients in the UAE. To study this, regions of the HLA-DRB1 and 
HLA-A genes from RA and control samples from Fujairah Hospital were sequenced 
and analyzed. Results indicated that there was minimal incidence of high risk HLA-
DRB1 SE or variations at position 11 and 13 of HLA-DRB1 in these samples. An 
asparagine at position 77 (Asn77) appeared to be a much strong biomarker for RA in 
this population (Odds ratio = 20.52, p-value = 0.0001985). Additionally, missense 
mutations Arg56 and Glu76 were also observed with significantly higher incidence in 
RA samples. The relevance of these variations warrant further investigation. In 
summary, HLA-A appears to be a stronger indicator of RA than HLA-DRB1 in the 
samples analyzed. 
 
Keywords: Rheumatoid arthritis, human leukocyte antigen, shared epitope, HLA-
DRB1, HLA-A.  
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 )cibarA ni( tcartsbA dna eltiT
 
بين مرضى التهاب ) ALH(البيض البشرية  الدم الكريات يلاتالتباين الوراثي لأل
 الفجيرةالمفاصل الروماتويدي في 
 صالملخ
) هو مرض مناعي ذاتي يتميز بالتهاب مزمن ARلتهاب المفاصل الروماتويدي (ا 
يحدث عندما يهاجم الجهاز المناعي أنسجة الجسم وأعضائه. السبب الأساسي  يصيب المفاصل.
الجينات لتهاب المفاصل الروماتيدي ليس مفهوما بالكامل، لكن الأدلة تشير إلى أن إللإصابة ب
أن مستضد كريات الدم  أيضا ذلك. لقد ثبت في با بوالهرمونات والعوامل البيئية يمكن أن تكون س
صل الروماتويدي. على وجه المفا وقوي لالتهاب ، هو عامل خطر )ALHالبيضاء البشرية ( 
 11والتغيرات في الموضع  1BRD-ALH) من ES، أظهرت منطقة الحلقة المشتركة (التحديد 
 . لتهاب المفاصل الروماتيديارتباًطا قويًا با A-ALHمن  77والموقع  1BRD-ALH من 31و
أن هذه الاختلافات يمكن أن ترتبط بمرضى التهاب المفاصل الروماتويدي  وقد وضعنا فرضية
-ALHدراسة وتقييم تسلسل الحمض النووي  مارات العربية المتحدة. وعليه تمفي دولة الإ
من مرضى إلتهاب المفاصل الروماتيدي من مستشفى الفجيرة ومقارنتها  A-ALHو  1BRD
-ALHبعينات لأشخاص غير مصابيين بالمرض. أشارت النتائج إلى أن هناك نسبة ضئيلة من 
 31و  11ع خطورة ضئيلة في الاختلافات في الموض وكذلك نسبة عالية المخاطر ES 1BRD
 77في هذه العينات. ظهر الحمض الأميني (اسبرجين) في الموضع  1BRD-ALH من
 ، 25.02) ليكون علامة حيوية قوية للمرض في هذه الفئة من السكان (نسبة الأرجحية = 77nsA(
 في موقعيين آخريين  لوحظت طفرات خطأ؛ ). بالإضافة إلى ذلك5891000.0 = pالقيمة 
أهمية هذه  . في فئة المصابيين بالمرض أعلى بكثير في عينات  بنسبة 67ulGو 65grA
 xi
 
 
 
 
 ARهو مؤشر أقوى على  A-ALH، يبدو أن التحقيق. باختصارالاختلافات يستدعي المزيد من 
 في العينات التي تم تحليلها.  1BRD-ALHمن 
 ، مستضد كريات الدم البيضاء، حلق التهاب المفاصل الروماتويدي :مفاهيم البحث الرئيسية
 . A-ALH ،1BRD-ALH، مشترك
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Chapter 1: Introduction 
1.1 Human Genome & Genetic Diversity 
Deoxyribonucleic acids (DNA) is the carrier of genetic information in most 
organisms. It is composed of four chemical bases: Adenine (A), Thymine (T), Cytosine 
(C) and Guanine (G). The Human Genome Project (HGP) was a ground-breaking 
undertaking that was initiated to determine the DNA sequence of the human genome 
and to map chromosomes to show the specific locations of genes (Holers, 2013). The 
first draft of the human genome sequence was completed in 2001. A natural extension 
of the HGP was to determine the genetic diversity among individuals and populations. 
Understanding genetic diversity in human population, and individual genetic 
variations, has several applications including the evaluation of the predisposition to 
genetic diseases, personalized medicine, pharmacology and even forensics (Smolen et 
al., 2016). Genetic variations or mutations result from changes in nucleotide sequence 
of the DNA; such as deletions, insertions, or even rearrangement of DNA sequences 
in the genome. DNA sequencing is an important technique used to define the exact 
order of nucleic acid bases to investigate gene function (Holers, 2013). The DNA of 
humans are 99.9% identical and the 0.1% difference accounts for several phenotypic 
variations and genetic disorders. While the genome plays a vital role encoding an 
individual’s genetic makeup, the environment also critically impacts an individual. A 
comprehensive understanding of gene-environment interactions for high incidence 
diseases, especially in families and populations, such as type 2 diabetes, cardiovascular 
diseases, sickle cell anemia, cancer, and autoimmune disorders, could help in early 
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detection, treatment and management of these conditions (Cush et al., 2010; Entezami 
et al., 2011; Genetics Home Reference, 2013). One such high incidence autoimmune 
disease with genetic basis is rheumatoid arthritis (RA) (Smolen et al., 2016). 
1.2 Overview of Rheumatoid Arthritis 
RA is the second most predominant autoimmune disorder (Holers, 2013). RA 
is defined as a chronic inflammatory joint disease affecting, in particular, hands and 
feet leading to cartilage and bone erosion (Smolen et al., 2016). It occurs when the 
immune system attacks the body's own tissues and organs. RA is estimated to be found 
in up to 1% of the population (Choy, 2012; Oka et al., 2014; Saxena et al., 2017; 
Smolen et al., 2016). It is more common in women than in men, with a rate of two to 
three times more in women, which may be related to hormonal factors (Genetics Home 
Reference, 2013; Boekel et al., 2001). Lower prevalence rates of RA have been 
described in Asian countries and rural Africa. The highest prevalence rate was 
described in American and European populations (Carmona et al., 2002). 
Geographical factors also play a role in RA since environmental factors are not equally 
distributed. In this case, area of residency, nutritional factors, socioeconomic factors 
and other factors affect the prevalence of RA (Martín et al., 2011). The general public 
associates the term “arthritis” with pain and stiffness in joints. Arthritis in Greek means 
inflammation (itis) of the joints (arthron). This term describes a collection of more than 
hundred joints disorders without inflammation (Shlotzhauer et al., 2014). The term 
“rheuma” made its first appearance in the first century referring to a substance, derived 
from phlegm that flows in the body. It was believed to originate in the brain and flowed 
3 
 
 
 
 
to various parts of the body causing ailments (West, 2014). The symptoms of RA 
include pain, swelling, and stiffness of the joint, while in serious cases the 
inflammation affects the bone, cartilage, and other tissues within the joint (Cush et al., 
2010). 
 RA is caused by a combination of genetic and environmental factors; however, 
in many cases the precise etiology is unknown. Variations in several genes have been 
studied as a risk factor for RA (Genetics Home Reference, 2013). Most of the genes 
implicated are known or thought to be involved in immune system function. 
1.3 History of Rheumatoid Arthritis 
RA was first described by Augustin Jacob Landré-Beauvais in 1800 at an 
asylum in France. He noticed the condition in poor patients, and suggested that the 
disease is gender-related as it affected women more than men. He thought that it was 
related to gout, which was then associated mostly with affluent patients. Thus, he 
called it Primary Asthenic Gout. However, his explanation of RA as gout, did not 
satisfy researchers in the field (Cush et al., 2010; Shlotzhauer et al., 2014). Sir Alfred 
Baring Garrod, an English physician during the mid to late 19th century, was the first 
person who differentiated gout from other arthritic conditions. His discovery was that 
patients with gout have uric acid in their blood, which was not the case in patients with 
arthritic conditions. In 1859, Sir Alfred published his classification of RA as a distinct 
disorder in a manuscript titled “Treatise on Nature of Gout and Rheumatic Gout” 
(Cush et al., 2010). 
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 Fifty years later, Sir Archibald Edward Garrod, the fourth son of Sir Alfred 
Baring Garrod, wrote about his father’s discovery in a book titled “A Treatise on 
Rheumatism and Rheumatoid Arthritis”. He was the first to use the term “Rheumatoid 
Arthritis” when referring to this disease. He demonstrated that RA appears during a 
period that was marked by increase in pollution, dietary changes, and lifestyle 
transformations. In his book, he suggested that RA is a problem inherited from one’s 
ancestors. He concluded this by studying skeletons found in some graves. 
Unfortunately, his book lacked profound evidence (Cush et al., 2010; Shlotzhauer et 
al., 2014). In Native American skeletons of the Mississippi River valley, RA had been 
identified as far back as 4500 BC. Some researchers demonstrated that RA originated 
as an infection in a small group of Native Americans; then it spread worldwide (Koehn 
et al., 2002). 
In 1912, Frank Billings suggested that RA was a response to chronic infection. 
Scientists tried to find a link between different types of infections and the development 
of RA. By the end of the 1920s, the culprit was thought to be tuberculosis and some 
other bacteria like Streptococcus and Mycoplasma. Later, medical research focused on 
viruses, rubella, and parvoviruses.  
In the 20th century, some researchers suggested that bacteria that inhabit our 
mouth and digestive tracts could cause an abnormal response of the immune system 
which may lead to the development of RA (Boekel et al., 2001).  In the mid-20th 
century, investigators began using X-rays as a popular technique for comparing skeleta 
of living patients. Their observations were dependent on the nature of soft tissue found 
in a living patient. Therefore, it was suggested that the signs symptomatic of RA 
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damage seen on dry skeletons may not have been produced by RA (Cush et al., 2010). 
In 1940, Norwegian Eric Waaler discovered the Rheumatoid Factor (RF) 
autoantibodies (Brink et al., 2016; Cantagrel & Degboe, 2016). RFs are autoantibodies 
against the Fc domain of immunoglobulin G (IgG). For over half a century, RFs have 
been used as a key marker of RA. 1.4 Genetic History of Rheumatoid Arthritis 
A large body of evidence suggests that there is an association between human 
leukocyte antigen (HLA) alleles and RA (Cantagrel & Degboe, 2016; Cush et al., 
2010; Weisman, 2011). It is considered to be the strongest genetic risk factor for the 
disease (Drongelen & Holoshitz, 2017). In 1977, Andrew J. McMichael and colleagues 
reported that there was an increased frequency of occurrence of Human Leukocyte 
Antigen (HLA)-Cw3 and HLA-Dw4 proteins in RA patients (Choy, 2012).  RJ. 
Winchester from the New York Sinai School of Medicine studied populations of 
patients with RA and families with multiple cases of RA, and provided definitive 
evidence that susceptibility to the disease is determined both by genetic factors 
associated with alleles of the major histocompatibility complex (MHC) as well as 
environmental factors. The development of seropositive, but not seronegative RA is 
associated with the presence in an individual of the HLA alloantigen HLA-DR4. A lot 
of genetic aspects of RA has been studied and is still under active investigation and 
research (Al-Mughales, 2015).   
1.4 Common Types of Arthritis 
 There are over hundred types of arthritis that can cause weakness, pain, and 
life-difficulties. According to Arthritis Foundation, the most common types of arthritis 
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that affect patient’s activity are osteoarthritis (OA), rheumatoid arthritis (RA), 
psoriatic arthritis (PsA), lupus, and gout.  The difference between RA and OA is the 
nature of the disease (Freeman, 2018 ). RA is an autoimmune disease where joints and 
sometimes other organs are attacked by an individual’s immune system, while OA is 
a degenerative joint disorder that results in wear and tear of joints.  OA is the most 
common chronic condition of the joints that occurs when the cartilage between joints 
starts to collapse. There are several factors that causes OA including genetic variations, 
obesity, injuries, metabolic disorders as well as joint diseases such as RA. On the other 
hand, the causes of RA are not fully understood. The reason for the sudden abnormal 
response of the immune system to body-tissues is yet to be clearly elucidated. 
However, it has been reported that hormones, environmental factors and genes are the 
leading causes of RA. The symptoms of OA and RA are quite similar which confuses 
patients and physicians. Based on the Arthritis Foundation, symptoms include joint 
pain, swelling or stiffness, joint tenderness and fatigue particularly occurring in the 
morning, and limited range of motions. Gout is a type of arthritis that causes 
inflammation, usually in one joint, which begins suddenly. Gouty arthritis is caused 
by the deposition of crystals of uric acid in a joint (Driver, 2019). Accordance to the 
Lupus Foundation of America, lupus is considered as a type of arthritis since many 
symptoms of arthritis are also present. Lupus is an autoimmune disease in which the 
immune system is very active. A long-period of inflammation leads to uncontrolled 
lupus or “lupus arthritis”. PsA is a form of arthritis which is developed by people with 
psoriasis (Mayo Clinic, 2018). PsA is believed to be caused by genes or infections and 
sometimes by other factors such as stress and injury. Symptoms of PsA include joint 
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pain, stiffness, skin problems, eyes problems, changes in nail color and shape and 
swelling in fingers and feet (Freeman, 2018 ).  
1.5 Pathophysiology of RA 
RA is one of the most prevalent forms of autoimmune arthritis that is 
characterized by inflammation of the joint lining the synovium. Synovial joints 
strengthen and support joints, including the cartilage, tendon, ligament, and muscle. 
Each of these structures are made up of different kind of tissues, and these tissues are 
made up of specialized cells (Figure 1) (Shlotzhauer et al., 2014). RA is a gradual 
inflammatory syndrome characterized by proliferation of the synovial membrane and 
constant uncontrolled inflammation resulting in chronic destructive polyarthritis 
(Hoxha, 2018). In RA the immune system does not recognize the body’s tissue and 
attacks it as if it was an invader. Subsequently, a cascade of immune reactions results 
in inflammation, thickening of synovial lining, angiogenesis and cartilage destruction 
(Brink et al., 2016; Yamamoto et al., 2015).  
1.6 Autoimmune Response 
The immune system is a complicated mechanism that enables the body to 
defend itself against invaders. The production of autoantibodies against specific or 
several self–antigens in the body is the hallmark of autoimmune disorders. The cause 
of such antibodies production remains unclear. RA has been classified as an 
autoimmune disease for nearly a century since the identification of RFs. RA is an 
inflammation of the synovium, caused by an interaction between fibroblast-like 
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synoviocytes and cells of the innate immune system (Gierut et al., 2017). The function 
of the innate immune system is to recruit immune cells to an infection site by producing 
chemical factors like cytokines followed by an activation of a cascade of several 
components of the immune system (Janeway et al., 2008).  
 40-65% of RA patients are seropositive and around 20% are seronegative. In 
seropositive patients, blood tests show the presence of antibodies that attack the body 
and lead to joints inflammation. Antibodies elevated in RA patients include RFs, anti-
citrullinated protein antibodies (ACPAs) or both (Nakken et al., 2017; Smolen et al., 
2016; Verheul et al., 2015). 
 
Figure 1: Schematic view of a normal joint (a) and a joint affected by RA (b). 
The joint affected by RA (b) shows increased inflammation and cellular activity  
( Choy, 2012). 
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1.7 Autoantibodies Associated with RA  
Over the past 25 years, an abundance of autoantibodies has been associated 
with RA and its activity. The discovery of these autoantibodies continue without 
reaching a comprehensive idea about its association with the disease (Choy, 2012). RF 
was an early autoantibody linked with RA that is present in about 75% of RA 
seropositive patients. Anti-RA33 antibodies was found in 36% of RA sera while anti-
calpastain was found in about 45% of RA sera (Brink et al., 2016; Nakken et al., 2017; 
Boekel et al., 2001; Verheul et al., 2015). Sa protein or citrullinated vimentin, was 
present in about 40% of the RA sera with high specificity (Brink et al., 2016; Nakken 
et al., 2017; Boekel et al., 2001; Verheul et al., 2015). Anti-citrullinated protein 
antibodies (ACPAs) are early markers for RA that are detectable before the onset of 
the clinical symptoms. ACPAs are the most specific autoantibodies used as RA 
markers. The role of ACPAs in RA, however, has not been clearly established. ACPAs 
are associated with the shared epitope (SE) (Figures 2 and 3) of HLA-DR1 and 
generated via T-helper cell and B-helper cell. Heavy chain binding protein (p68) and 
glucose-6-phosphate isomerase are also found in RA patients (Brink et al., 2016; 
Holers, 2013; Nakken et al., 2017; Boekel et al., 2001; Woude & Catrina, 2015; 
Verheul et al., 2015). 
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Figure 2: Antigens are the molecules recognized by the immune response, while 
epitopes are sites within antigens to which antigen receptors bind (Janeway et al., 
2008). 
 
Figure 3: An antibody binds an antigen directly, whereas a T-cell receptor binds a 
complex of antigen fragment and self-molecule (Janeway et al., 2008). 
1.8 Genetic Association of RA  
Both genetic and environmental factors play a role in RA. Genetic factors play 
a strong role in RA progression and severity. Variations in several genes have been 
studied as risk factors for RA. Most of these genes are known or believed to be 
involved in immune system and forms part of the major histocompatibility complex 
antigen 
epitope 
antibody 
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(MHC) or specifically human leukocyte antigen (HLA) in humans (Firestein & 
McInnes, 2017). It has been established that the most common components of HLA 
class II such as HLA-DRB1 is involved in several autoimmune disease including type 
1 diabetes, Graves’ disease and RA (Gough et al., 2007). Previous studies have 
demonstrated that RA progression and severity is associated with HLA-DRB1 
polymorphisms (Weyand et al., 2000; Barnetche et al., 2002). 
1.9 Major Histocompatibility Complex (MHC) 
MHC is a gene family that exists in many species. It consists of more than 200 
genes. In humans, the MHC genes cluster on chromosome 6. The cytogenetic location 
of MHC in human is on the short arm within 6p21.3 and spans around 4,000 kilobases 
(Mizuki & Kimura, 1996). HLA is the human form of MHC. MHC encodes a set of 
membrane glycoproteins called the MHC molecules. Genes in this complex are 
categorized into three main groups: class I, class II, and class III (Genetics Home 
Reference, 2009). The genes encoding the α chains of MHC class I molecules and the 
α & β chains of MHC class II molecules are linked within the complex (Figure 4) 
(Janeway et al., 1996). MHC class I proteins are found in all cells while MHC class II 
proteins are found in phagocytes. T helper cells recognize antigen in association with 
MHC II and T cytotoxic cells recognize antigen in association with MHC I (Janeway 
et al., 2008). The figure below shows the relative position of MHC class I and class II 
genes on the short arm of chromosome 6 at position 6p21.3 along with specific exons 
within these gene with known variations associated with RA (Figure 5) (Warren et al., 
2012). 
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Figure 4: The structure of an MHC class I molecule (Transplantation Immunology, 
2015). 
 
Figure 5: The relative position of the HLA genes on the short arm of chromosome 6 
and the exons to be considered (Warren et al., 2012). 
1.10 Class I MHC/HLA Genes  
MHC I is made of an α chain (43 kDa) and small peptide called β2-
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macroglobulin (12 kDa). The extracellular domains show variability in their amino 
acid sequences, resulting in grooves with different shapes (Figure 6). MHC I binds to 
short peptides of 8-10 amino acid and T cytotoxic cells recognize antigen associated 
with MHC I (Janeway et al., 2008). 
 
Figure 6: The structure of an MHC class I molecule (Janeway et al., 2008) 
In humans, there are three major loci that code for MHC I molecules (HLA-A, 
HLA-B and HLA-C). Within a locus, there are different allelic forms of the molecules. 
For example, HLA-A2 and HLA-Aw68 class I molecules differ from one another at 
13 amino acid residues. These distinctions in allelic forms of HLA molecules results 
in dramatic differences in the shape of the groove of the molecule, where foreign 
peptides are accommodated. Each individual can express up to two types of HLA-A 
alleles, one each inherited from a set of parents. Some individuals will inherit the same 
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HLA allele from both parents that thereby decreasing the individual’s HLA diversity. 
The MHC is polymorphic and exhibits codominant expression. Thus, most individuals 
are likely to be heterozygous at each locus. Because the human population is 
extensively outbred, the MHC genetics in humans is extremely complex (Figure 7) 
(Janeway et al., 2008).   
 
Figure 7: Expression of MHC alleles is codominant (Janeway et al., 2008). 
1.11 Class II MHC/HLA Genes  
The class II genes of MHC provides instructions for making proteins present 
on the surface of certain immune system cells (Janeway et al., 1996). The genetic locus 
encoding class II molecules is known as the D region in humans. The D region is 
further subdivided into several groups. There are seven super types of class II HLA-D 
genes (main DR, DR4, DRB3, main DQ, DQ7, main DP and DP2) (Greenbaum et al., 
2011). Like the HLA class I genes, HLA-D class II genes also exhibit polymorphism 
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and codominant expression. MHC class II is always expressed by B lymphocytes and 
dendritic cells. It is composed of an α chain (30-34 kDa) and a β chain (26-29 kDa). 
In MHC class II, the extracellular domains show variability in their amino acid 
sequences resulting in grooves with different shapes (Figure 8). The length of the 
peptides bound is not constrained. It could be at least 13 amino acid long and can be 
much longer. T helper cells recognize antigen in association with MHC II (Janeway et 
al., 2008; Janeway et al., 1996). In plentiful numbers of individuals,  HLA-DR cluster 
consist of an additional β chain gene and its product can pair with the DRα chain ( 
Janeway et al., 1996; Scrivo et al., 2007). 
 
 
 
 
 
 
 
Figure 8: The structure of an MHC class II molecule  (Janeway et al., 2008). 
1.12 Class III HLA Genes  
Class III HLA genes encode complement components that show no structural 
similarity to ether class I or class II molecules. MHC class III region resides between 
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the MHC class I and class II regions (Wennerstrom et al., 2013). These genes, along 
with genes encoding tumor necrosis factor (TNF), separate HLA class II and HLA 
class I genes on chromosome 6 in humans (Figure 9) (Matzaraki et al., 2017). 
 
 
Figure 9: The genetic organization of the major histocompatibility complex (MHC) 
in human  (Janeway et al., 2008). 
1.13 MHC Functions and Pathways 
The function of MHC is to bind to peptide fragments from infectious agent and 
present them on the cell surface. Appropriate T cells can then recognize the infected 
cell and destroy it. This mechanism obstructs pathogens from dodging the immune 
system. Class I and class II of MHC molecules binds peptides to T cells, however, 
each type has its own pathway for binding  peptides (Figure 10) (Janeway et al., 2008; 
Kobayashi & Elsen, 2012).  
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Figure 10: The (a) MHC class I and (b) MHC class II antigen-presentation pathway 
(Kobayashi & Elsen, 2012). 
1.14 Nomenclature and HLA Classifications 
HLA started as a list of antigens identified because of transplant rejections (Ka 
et al., 2017; Thorsby, 2009). The antigens were initially identified by massive 
statistical analysis of the interactions between blood types. This operation is in 
accordance with the principle of serotypes. HLA genes of the host consists of different 
antigens from those found on the surface of infectious agents. HLAs are alloantigen, 
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which are responsible for binding to non-self-antigens from member of the same 
species. In another word, the alloantigen is present only in some, but not all, members 
of a species and it stimulates the production of alloantibody by individuals lacking that 
antigen in grafting and organ transplants or even in blood group. This determines the 
acceptances or rejection of the organs and blood between individuals (Janeway et al., 
2008). HLA vary between individuals due to genetic differences. One of the most 
complex regions of the human genome is the HLA locus. In spite of the fact that it 
represents only 0.3% of human genome, it constitutes 1.5% of genes in OMIM, and 
6.4% of SNPs in the genome are based in this region (Ka et al., 2017; Thorsby, 2009). 
Many different versions or alleles of HLA genes have been identified by researchers. 
Each allele is assigned a specific notation. The most recent HLA naming system was 
developed in 2010 by the WHO Committee for Factors of the HLA System. They 
developed a systematic naming convention for identifying the variations in HLA 
alleles. There are two types of MHCs, Class I and Class II MHCs are named with the 
same system. Alleles that started with “HLA” represent the human MHC genes. The 
next part (HLA-A or HLA-B) identifies which gene the allele is a modification of. 
Each HLA allele has a unique number that consists of four set of digits separated by 
colons. The digits before the colon represents the type that is associated with the 
serological antigen supported by an allotype, the allele of the antibody chains found in 
the individual. The digits after the colon is used to list the subtypes of the DNA 
sequences that have been identified. For example, in HLA-DRB1*04, the HLA is a 
prefix, DRB1 is the gene followed by a separator and 04 is the allele group. Sometimes 
four digits follow, for example HLA-DRB1*04:01, in which case 01 is a specific HLA 
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protein. The third group of digits, for example 02 in HLA-DRB1*04:01:02, refer to 
allele variants which produce same protein. The fourth set of digits are used for non-
coding region of the gene (Figure 11,12). The final aspect of HLA naming is a letter 
used to denote changes in expression. There are six letters, each with a different 
meaning (Table 1) (Marsh & System, 2011; Scally et al., 2013). 
  
Figure 11: Interpretation of digits in HLA genes (Marsh & System, 2011). 
 
Figure 12: Nomenclature of HLA Alleles. 
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 Table 1: The final aspect of HLA naming 
Letter Significance 
N Null Allele (Presents a non-functional protein) 
L Lower than normal cell surface expression 
S Soluble protein absent from the cell surface 
Q Questionable (allele may affect the expression) 
C Protein is found in cytoplasm and absent on cell surface 
A Aberrant or irregular expression 
1.15 Association of HLA Genes with RA 
The inheritance pattern of RA is unclear due to the involvement of numerous 
genetic and environmental factors. The HLA loci have been identified as the genes 
most associated with RA (Kochi et al., 2014; Viatte et al., 2015; Weyand et al., 2000). 
Several allelic variants of HLA gene have been associated with RA. Studies have 
indicated that RA is associated primarily with HLA-DRB1 alleles, especially 'HLA-
DRB1*04' allele. HLA-DR is a cell surface receptor that provides information to make 
protein functions in immune system response. It provides instructions to present 
peptide antigens to the immune system to elicit or suppress T-helper cell responses 
(Janeway et al., 2008; Ruyssen-Witrand et al., 2015; Scally et al., 2013; Viatte et al., 
2015; Wennerström et al., 2013). The association of the HLA-DRB1 with RA is 
strongly associated with conserved sequences at amino acid positions 70-74 in the 
protein referred to as the shared epitope (SE) (Ruyssen-Witrand et al., 2015; Scally et 
al., 2013). This conserved region with the sequence QKRAA/QRRAA/RRRAA, 
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which involves alleles HLA-DRB1*01:01, HLA-DRB1*04:01, HLA-DRB1*04:04, 
HLA-DRB1*10:01, have been strongly associated with RA (Ruyssen-Witrand et al., 
2015). Additional classifications of HLA-DRB1 associated with RA has expanded this 
to the presence of an aspartic acid 'D' at position 70 and the DERAA SE motif between 
positions 70-74. Further, it has been demonstrated that the amino acid at position 11 
and 13 also increases the risk of RA (Ruyssen-Witrand et al., 2015). The presence of 
Val11 in HLA-DRB1 has been reported to be strongly associated with seropositive 
RA, while the amino acids most associated with seronegative RA is HLA-DRB1 were 
Ser11 and Leu11 and the allele type HLA-DRB1*03. It has also been shown that HLA-
A Asn77 is also significantly associated with seropositive RA (Figure 13) (Han et al., 
2014). 
 
Figure 13: 3D models of HLA proteins with amino acid positions that are 
significantly associated with RA (Han et al., 2014). 
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Figure 14: 3D models of HLA proteins with additional amino acid positions that are 
known to be associated with RA (Raychaudhuri et al., 2012). 
Furthermore, three additional positions in HLA-DRB1 - His13, Lys71, and 
Ala74 - and single amino acid polymorphism in HLA-B - Asp9 - and HLA-DP1 - Phe9 
– were associated with an increased risks of  seropositive RA  (Figure14) (Greenbaum 
et al., 2011; Raychaudhuri et al., 2012). 
It was reported that in Black Sea Turkish population, the frequency of HLA-
DRB1*01, *04, and *09 alleles are higher in RA patients and the conserved SE at 
position 70-74 is commonly QKRRA (Uçar et al., 2012). In African Americans 
population, a Val11 variation, corresponding to allele *09:01, was observed to impart 
high RA risk, which was also the same allele for RA in the Korean population. A recent 
study established that in European ancestry, HLA-DRB1*04:01, *04:04, and *01:01 
are the most frequent RA risk alleles, whereas in East Asian populations, HLA-
DRB1*04:05 and *01:01 were the most frequent RA risk alleles (Yamamoto et al., 
2015). In addition, several subtypes of the DR4 allele, such as *04:02 and *04:03 
appear to confer protection against the disease (Yamamoto et al., 2015). The protective 
effects of DRB1 allele, DRB1*13:02, in Japanese RA has also been reported (Oka et 
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al., 2014). A study involving the typing of HLA-DRB1 in Saudi Arabian RA patients 
found that HLA-DRB1*04 followed by HLA-DRB1*08 and HLA-DRB1*10 are 
alleles that could be used as predictors for RA. Additionally, the frequency of HLA-
DRB1*06 was observed to be lower in RA compared to control (Al-Swailem et al., 
2006). Table 2 provides a summary of HLA-DRB1 alleles that have been reported to 
be associated with RA in various populations. 
Table 2: Distribution of HLA-DRB1 alleles and genotypes frequencies in RA among 
different population. 
Population HLA-DRB1 allele Reference 
Japanese 
*04 *09:01 *15 
(Al-Swailem et al., 2006; 
Oka et al., 2014; Shimane 
et al., 2013) 
African American *09:01   (Reynolds et al., 2014) 
Korean 
*09:01 *04:05  
(Al-Swailem et al., 2006; 
Reynolds et al., 2014) 
European *01:01 *04:01 *04:04 (Reynolds et al., 2014) 
Turkish *01 *04 *09 (Uçar et al., 2012) 
Saudi *01 *04 *08 (Al-Swailem et al., 2006) 
French *01   (Uçar et al., 2012) 
Latin Americans *01   (Uçar et al., 2012) 
Asians 
*01 *04:05  
(Uçar et al., 2012; 
Yamamoto et al., 2015) 
Caucasians *01 *09  (Uçar et al., 2012) 
Chileans *09   (Uçar et al., 2012) 
Syrian *01:01 *04:04 *04:05 (Saxena et al., 2017) 
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1.16 RA in United Arab Emirates  
 Over 20% of UAE’s population suffer from at least one type of arthritis 
(Carmona et al., 2002). RA is the most common inflammatory arthritis (Drongelen & 
Holoshitz, 2017).  In UAE, RA is widespread with delayed diagnosis. Dubai Bone and 
Joint Center classifies patients with RA by the symptoms and their ages. Only 
individuals who are 16 and above and have RA symptoms are categorized as RA 
patients (Badsha et al., 2008). Additionally, more females were diagnosed with RA 
than males (Badsha et al., 2008; Saxena et al., 2017). A recent study evaluated the 
factors causing RA in Arab populations. RA patients from Jordan, the Kingdom of 
Saudi Arabia, Lebanon, Qatar, and the United Arab Emiratis were examined to check 
the genetics and clinical features of the disease. The study concluded that HLA-DRB1 
amino acid position 11 was strongly associated with seropositive RA in Arabs (Saxena 
et al., 2017).  
1.17 Whatman FTA Technology 
 Flinders Technology Associates (FTA), or now Whatman FTA Card, is a filter 
paper based system manufactured by GE Health Care that provides a safe and reliable 
technique for storage of DNA at the room temperature for several years (Ndunguru et 
al., 2005). It has been reported by the manufacturers that DNA remains stable for at 
least 17 years or more. As proof, researchers were able to generate short tandem repeat 
(STR) data with good signal strength from DNA from 22-years-old blood (Mullen et 
al., 2009; Whatman FTA Technology). The FTA card is a special type of filter paper 
(Figure 15A) which consist of two types of reagents – one that regulate cell lysis and 
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protein denaturation and the other that protect DNA from denaturation (Entezami et 
al., 2011; Santos, 2018). Different kind of samples (blood, bacteria, buccal cells, 
cultured cells, plant material, and more) can be applied either directly or with a swab 
to FTA cards (Whatman). The cards are white, pink, or purple color. Pink and purple 
include a dye which turns white when colorless samples are applied (Figure 15B) 
(Whatman FTA Technology). FTA technology is widely for human DNA collection, 
archiving of nucleic acids for forensic applications and PCR-based genotyping 
(Ndunguru et al., 2005). After drying the sample, a small disc from the card is removed 
using a puncher to recover nucleic acids. The discs are washed with FTA reagents, and 
can be directly used for amplification by PCR. Since FTA cards require only a few 
drops of blood, which could significantly reduce the trauma associated with blood 
collection especially in children, as well as reduce the chance of infection, this study 
decided to investigate FTA cards as a means of collecting and extracting DNA for 
routine testing. 
A       B  
 
Figure 15: (A) Whatman FTA cards (B) FTA card that turns white when colorless 
samples are loaded  (Avantor; Cole-Parmer Canada Company). 
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1.18 Hypothesis 
 The HLA loci have been established as a strong risk factor associated with RA. 
Specifically, the SE region of HLA-DRB1 has been documented as the strongest 
indicator. Additionally, other variations at position 11 and 13 of HLA-DRB1 and 
position 77 of HLA-A are also very good risk factors. The hypothesis of this study was 
that these variations could be observed in RA patients in the UAE. 
  
1.20 Objective of the Study 
 The main aim of this study was to understand the variation of HLA genes 
in RA patients from Fujairah Hospital in UAE. Identification of variations in HLA 
alleles could help in understanding the possible genetic cause of RA in this region 
which could further be expanded to the population of UAE at a later stage. Specifically, 
this would involve identifying the variations in the genes HLA-A from class I of MHC 
and HLA-DRB1 from class II of MHC, which are two genes that harbor variations 
associated with RA. Blood samples were collected and loaded on Whatman FTA card 
and exon 2 and 3 of HLA-A and exon 2 of HLA-DRB1 would then be amplified using 
polymerase chain reaction (PCR) and sequenced to compute the incidence of the 
known variants associated with RA. 
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Chapter 2: Methods 
2.1 Ethical Approval 
Ethical approval was obtained from the Center of Research and Statistics, 
Ministry of Health and Prevention (MOHAP) to collect samples from Fujairah 
Hospital. Ethical approval no: MOHAP /DXB-REC-SUB-30/2017, was granted on 23 
August 2017 and renewed on 10 December 2018 up to 9 December 2019. 
2.2 Patients and Controls 
 To be eligible for the study, patients had to be Emirati, should have been 
clinically diagnosed with RA, be at least ≥ 18 years of age, and be able to sign an 
informed consent. Healthy controls included individuals who had not shown any 
clinical symptoms of RA. A total of 54 RA patient samples and 44 healthy control 
samples were analyzed in this study. Subjects were enrolled from Fujairah Hospital 
during the period 25 August 2017 to March 2018. 
2.3 Sample Collection 
2 ml of whole blood was collected from patients and controls by venipuncture 
into vacuum collection tubes containing dipotassium EDTA (Ethylene Diamine 
Acetate). One drop (around 50 μl) was applied to a Whatman™ FTA Micro Card (Fig 
16). Cards were dried at room temperature, transported to Department of Biology, 
United Arab Emirates University, for further analysis. 
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Figure 16:  FTA card spotted with human whole blood. 
2.4 Storage Condition 
 Whatman™ FTA cards that contained blood samples were stored at room 
temperature in a safe cabinet at UAE University with coded numbers. Original blood 
samples collected in EDTA tubes were stored at -50°C in a safe room at Fujairah 
Hospital.  
2.5 DNA Extraction  
 FTA cards that contained blood samples were punched twice using Harris® 
Uni-CoreTM 1.2 mm puncher (Figure 17) and placed in a PCR tube for washing. To 
avoid cross contamination between samples, an equivalent number of discs were taken 
from a blank FTA cards after each sample. The two small punched discs were washed 
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for 45 minutes in 200 µl of Whatman FTA purification reagent. The discs were then 
washed for 10 minutes in 200 µl of 1 mM TE buffer. The washed discs were left to 
dry at room temperature for up to 30 minutes. The two washed discs were then used 
for PCR. Using FTA card for PCR does not require DNA extraction or quantification 
since the amount of DNA in the disc is sufficient for PCR . 
 
Figure 17: Harris® Uni-CoreTM 1.2 mm puncher. 
2.6 Primers 
The sequence of HLA-DRB1 gene and HLA-A gene were retrieved from 
Ensemble genome browser. The sequences were further cross checked with the 
sequence obtained from National Center for Biotechnology Information (NCBI)  
database. The coding exons 2 and 3 were marked and primers were designed that 
covered this region. Melting temperature and GC content of each primer were also 
calculated. Designed primers were purchased from Macrogen (Korea). The optimum 
conditions for the primers were then determined experimentally using multiple PCR 
test runs. The list of primers and their optimal conditions are given in Table 3. 
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Table 3: Primers set used in PCR to amplify different HLA genes. 
  
  
Gene Forward Primer Reverse Primer 
Annealing 
Temperature 
(°C) 
Annealing 
Time 
(sec) 
HLA-DRB1 
(exon 2) 
5’- GATGGTGGCGTCGCTGTC-3’ 5’-GCTCTCAGAACTGCTTGCT-3’ 59 35 
5’-GAAGACGGAGGATGAGCTCC-3’ 5’-GAACTGCTTGCTCCGGACTG-3’ 59 35 
HLA-A 
(exon 2) 
5’-TTGGGTGTCGGGTTTCCAGAGA-3’ 5’-CTCTCCCGGGACAAGGGTCTC-3’ 66 40 
5’-TCGTCGCGGTCGCTGTTCTA-3’ 5’-CTTCGGGGTGGATCTCGGACC-3’ 66 40 
HLA-A 
(exon 3) 
5'-GAGACCCTTGTCCCGGGAGAG-3' 5'-GTCAGAGAGCAGGGCGGAACC-3' 67 40 
5'-CAGGAGACACGGAATGTGAAG-3' 5'-CAATTGTCTCCCCTCCTTGTG-3' 61 35 
3
0
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2.7 PCR amplification 
 The Go Taq® Green Master Mix (Promega, USA), which is a premixed ready-
to-use solution, was used in this study. Go Taq® Green Master Mix contains Taq DNA 
polymerase, dNTPs, MgCl2 and reaction buffers at optimal concentrations. A reaction 
volume of 50 µl was used for each PCR run. Two FTA discs were added to each PCR 
tube.  The reaction conditions used in the Thermal Cycler (Figure18) were as follows: 
1 cycle at 95ºC for 3 minutes followed by 34 cycles of denaturation at 95ºC for 30 
seconds, annealing at temperature and time provided in Table 3, and finally extension 
at 72ºC for one minute. Amplified products were visualized on 1.5% (w/v) agarose gel 
using electrophoresis. 
 
Figure 18: BioRad T100™ Thermal Cycler. 
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2.8 Gel Electrophoresis  
1.5% (w/v) agarose CSL-AG500 (Cleaver Scientific) gel was prepared using 
0.75 grams of agarose in 50 ml of 1 X Tris-Borate EDTA (TBE) buffer (0.89 M Tris-
borate, 0.032 M EDTA, pH 8.3) and heated in a microwave for 1-2 minutes until it 
dissolved completely. The gel mixture was cooled to room temperature and 2 µl of 
ethidium bromide was added. When the gel had cooled adequately, it was poured into 
a gel tray. Once the gel solidified, 5 µl of 100 bp DNA ladder (N3231S-BioLab-
ThermoFisher) was added followed by PCR products which were added immediately 
into wells without using a loading dye. The Go Taq® Green Master Mix used includes 
two dyes that allowed the monitoring of the progress of electrophoresis. Bio Rad 
PowerPac™ Basic machine was used for electrophoresis. The voltage and current were 
set at 120 V and 400 A, respectively, and the gel was allowed to run for 20 minutes. It 
was subsequently visualized and recorded using a Compact Digimage System, UVDI 
series gel documentation system.  
2.9 Purification of PCR products 
The amplified PCR products were purified using the Norgen PCR purification 
kit (Norgen Biotek, Canada). For this purpose, the binding buffer provided in the kit 
was added in 5:1 ratio to the PCR product. This was vortexed and pulse-spun briefly. 
The mixture was then transferred into a column provided in the kit and centrifuged for 
1 minute at 8000 rpm. The flow-through was discarded and 500 µl of washing buffer 
(96-100% ethanol) was added to the column and centrifuged for 1 minute at 10,000 
rpm. The flow-through was discarded again and the spun for 2 minutes at 14,000 rpm 
in order to dry the column. The column was then assembled with the provided 1.7 mL 
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elution tube. To increase DNA concentration 10 µl of elution buffer was added to the 
center of the column bed and kept standing at room temperature for 1 minute. The 
column was then centrifuged for 2 minute at 14,000 rpm. The last step was repeated 
once more. Quantity and quality of the purified DNA was evaluated by loading 1µl of 
purified DNA in NanoDrop 2000/c (Thermo Fisher Scientific, USA) which is a 
microvolume spectrophotometers.  
2.10 DNA Sequencing 
Samples that satisfied the required quality and quantity were sent to Macrogen, 
(Korea) for sequencing. The sequences and chromatograms were provided by 
Macrogen which were then analyzed further. 
2.11 Analysis of Sequencing Data 
FinchTV chromatogram viewer version 1.4.0 (Geospiza) was used to visualize 
the chromatograms. BioEdit Sequence Alignment Editor Version v7.0.5 (Tom Hall 
Ibis Therapeutics) and JalView (Waterhouse et al., 2009) were used to perform 
sequence alignment. Reference sequences for HLA-DRB1 (NCBI Accession: 
NG_029217) and HLA-A (NCBI Accession: NG_029921) were obtained from NCBI 
RefSeq database. Phylogenetic trees were generated using MEGA 6 (Kumar et al., 
2016) using the Maximum Likelihood algorithm (Kumar et al., 2016).  
2.12 HLA Allele Type Determination 
A custom BLAST server containing all known HLA sequences obtained from 
HLA Nomenclature (http://hla.alleles.org) (Figure 19) was used for HLA allele 
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determination. Following the convention, for the class I gene, HLA-A, sequences of 
exons 2 and 3 were combined for allele type determination. For the class II gene, HLA 
DRB1, sequence of exon 2 was used for allele type determination using BLAST. HLA  
allele type frequencies were then computed.  
 
Figure 19: A custom BLAST server (http://compbio.uaeu.ac.ae/blast-hla) to search 
HLA sequences obtained from HLA Nomenclature (http://hla.alleles.org) 
2.13 Homology Modeling 
To locate the spatial orientation of the variations with higher incidence in 
patients, homology models of the mutant HLA proteins were generated using the 
online SWISSMODEL server (https://swissmodel.expasy.org/). The obtained models 
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were visualized in VMD 1.9.2 (Humphrey et al., 1996) and the Schrodinger Suite 
2018-1 (Schrödinger, 2018). 
2.14 Statistical Analysis 
 For computation of odds ratio for specific variations, Fisher’s exact test was 
performed in R after generating contingency tables. To identify if there are genetic 
differences between patient and control groups, Fixation Index (FST) was computed 
using Arlequin 3.5.2 (Excoffier & Lischer, 2010). To identify if some or all of the 
patient and control samples cluster separately, Principal Component Analysis (PCA) 
was performed using aligned DNA sequences. The adegenet library was employed in 
R version 3.6.0 for performing PCA and plotting the principal components.  
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Chapter 3: Results 
 
3.1 HLA Gene PCR Amplification 
PCR was used to amplify genomic region encompassing exon 2 of HLA-DRB1 
and exons 2 and exon 3 of HLA-A. These are regions essential for HLA typing and 
also known to harbor variations strongly associated with RA. Figures 20, 21 and 22 
are sample gel electrophoresis images that shows bands of the expected size. HLA-
DRB1 exon 2 amplicon has size 529 bp, HLA-A exon 2 is 705 bp, and HLA-A exon 
3 is 598 bp. These samples were then purified and sent for DNA sequencing using the 
same primers used for PCR. 
 
Figure 20: Gel electrophoresis image of PCR products of HLA-DRB1 exon 2. 
 
Figure 21: Gel electrophoresis image of PCR products of HLA-A exon 2. 
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Figure 22: Gel electrophoresis image of PCR products of HLA-A exon 3. 
Chromatograms obtained from sequencing were inspected using Finch TV 
Viewer (Figure 23) and the sequences were aligned using BioEdit Sequence Alignmen 
Editor and JalView (Waterhouse et al., 2009) to identify locations that harbor 
variations (Figures 24-26). 
 
Figure 23: Chromatogram of an HLA-DRB1 sample visualized in FinchTV viewer. 
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Figure 24: Sequence alignment of sample HLA-DRB1 exon 2 sequence with the reference HLA-DRB1 sequence obtained from NCBI 
(NG_029921). Sequence alignment was performed in JalView (Waterhouse et al., 2009). 
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Figure 24: Sequence alignment of sample HLA-DRB1 exon 2 sequence with the reference HLA-DRB1 sequence obtained from NCBI 
(NG_029921). Sequence alignment was performed in JalView (Waterhouse et al., 2009) (Continued). 
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Figure 24: Sequence alignment of sample HLA-DRB1 exon 2 sequence with the reference HLA-DRB1 sequence obtained from NCBI 
(NG_029921). Sequence alignment was performed in JalView (Waterhouse et al., 2009) (Continued). 
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Figure 24: Sequence alignment of sample HLA-DRB1 exon 2 sequence with the reference HLA-DRB1 sequence obtained from NCBI 
(NG_029921). Sequence alignment was performed in JalView (Waterhouse et al., 2009) (Continued). 
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Figure 25: Sequence alignment of sample HLA-A exon 2 sequences with the reference HLA-A sequence obtained from NCBI 
(NG_029217). Sequence alignment was performed in JalView (Waterhouse et al., 2009). 
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Figure 25: Sequence alignment of sample HLA-A exon 2 sequences with the reference HLA-A sequence obtained from NCBI 
(NG_029217). Sequence alignment was performed in JalView (Waterhouse et al., 2009) (Continued). 
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Figure 26: Sequence alignment of sample HLA-A exon 3 sequences with the reference HLA-A sequence obtained from NCBI 
(NG_029217).  Sequence alignment was performed in JalView (Waterhouse et al., 2009). 
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Figure 26: Sequence alignment of sample HLA-A exon 3 sequences with the reference HLA-A sequence obtained from NCBI 
(NG_029217).  Sequence alignment was performed in JalView (Waterhouse et al., 2009) (Continued). 
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3.2 HLA-DRB1 Allele Typing 
 Allele typing of a HLA class II gene like HLA-DRB1 is normally performed 
with the sequence of exon 2. The exon 2 sequence of HLA-DRB1 was used as the 
input to perform a BLAST search against the HLA allele database deployed in a 
custom BLAST server in the lab (http://copbio.uae.ac.ae/blast-hla/). BLAST results 
were interpreted to identify the HLA-DRB1 allele type up to 4-digit resolution for 
control and patient samples. Allele types determined for controls are listed in Table 4 
and a summary of the incidence of each allele type is provided in Table 5, while the 
allele types determined for patients are listed in Table 6 and the corresponding 
summary in Table 7.  
Table 4: HLA-DRB1 allele type in control (C) samples. 
Sample Allele 
C1 DRB1*16:01 
C2 DRB1*16:02 
C3 DRB1*16:02 
C4 DRB1*16:01 
C5 DRB1*16:01 
C6 DRB1*16:02 
C7 DRB1*16:02 
C8 DRB1*16:02 
C9 DRB1*16:02 
C10 DRB1*16:02 
C11 DRB1*16:02 
C12 DRB1*16:02 
C13 DRB1*16:02 
C14 DRB1*15:02 
C15 DRB1*16:02 
C16 DRB1*16:02 
C17 DRB1*16:01 
C18 DRB1*16:02 
C19 DRB1*16:02 
C20 DRB1*16:02 
47 
 
 
 
 
Table 4: HLA-DRB1 allele type in control (C) samples (continued). 
Sample Allele 
C21 DRB1*16:02 
C22 DRB1*16:02 
C23 DRB1*16:02 
C24 DRB1*16:02 
C25 DRB1*16:02 
C26 DRB1*16:02 
C27 DRB1*16:02 
C28 DRB1*16:02 
C29 DRB1*16:02 
C30 DRB1*16:02 
C31 DRB1*16:01 
C32 DRB1*16:02 
C33 DRB1*15:03 
C34 DRB1*16:01 
C35 DRB1*15:03 
C36 DRB1*16:02 
C37 DRB1*16:02 
C38 DRB1*16:02 
C39 DRB1*16:01 
C40 DRB1*16:01 
C41 DRB1*15:02 
C42 DRB1*16:02 
C43 DRB1*16:02 
Table 5: Summary of HLA-DRB1 allele types in control samples at 4-digit and 2-
digit resolutions. 
Allele Count (4-digits) Count (2-digits) 
DRB1*15:02 2 
4 
DRB1*15:03 2 
DRB1*16:01 8 
39 
DRB1*16:02 31 
Total 43 43 
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Tables 4 and 5 show that the most frequent HLA-DRB1 allele in control samples is 
DRB1*16. It was found in 39 samples out of 43 while the DRB1*15 allele comes 
next with 4 samples out of 43. 
Table 6: HLA-DRB1 allele types in patient (RA) samples. 
Sample Allele 
RA1 DRB1*16:02 
RA2 DRB1*16:02 
RA3 DRB1*16:02 
RA4 DRB1*15:01 
RA5 DRB1*10:01 
RA6 DRB1*15:02 
RA7 DRB1*16:02 
RA8 DRB1*16:02 
RA9 DRB1*16:02 
RA10 DRB1*16:02 
RA11 DRB1*16:02 
RA12 DRB1*15:02 
RA13 DRB1*01:02 
RA14 DRB1*16:01 
RA15 DRB1*16:02 
RA16 DRB1*16:02 
RA17 DRB1*16:02 
RA18 DRB1*16:02 
RA19 DRB1*16:02 
RA20 DRB1*16:02 
RA21 DRB1*16:01 
RA22 DRB1*15:01 
RA23 DRB1*16:01 
RA24 DRB1*15:02 
RA25 DRB1*15:01 
RA26 DRB1*15:02 
RA27 DRB1*15:01 
RA28 DRB1*16:01 
RA29 DRB1*15:02 
RA30 DRB1*15:01 
RA31 DRB1*15:02 
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Table 6: HLA-DRB1 allele types in patient (RA) samples (continued). 
Sample Allele 
RA32 DRB1*16:01 
RA33 DRB1*16:01 
RA34 DRB1*15:02 
RA35 DRB1*16:01 
RA36 DRB1*15:114 
RA37 DRB1*16:02 
RA38 DRB1*16:01 
RA39 DRB1*16:01 
RA40 DRB1*15:02 
RA41 DRB1*16:01 
RA42 DRB1*16:02 
RA43 DRB1*16:02 
RA44 DRB1*16:02 
RA45 DRB1*16:01 
RA46 DRB1*16:02 
RA47 DRB1*15:01 
RA48 DRB1*16:02 
RA49 DRB1*16:01 
RA50 DRB1*16:01 
RA51 DRB1*16:01 
RA52 DRB1*16:01 
RA53 DRB1*16:01 
RA54 DRB1*16:01 
 
Table 7: Summary of HLA-DRB1 allele types in RA samples at 4-digit and 2-digit 
resolutions. 
Allele Count (4-digits) Count (2-digits) 
DRB1*01:02 1 1 
DRB1*10:01 1 1 
DRB1*15:01 6 
15 DRB1*15:02 8 
DRB1*15:114 1 
DRB1*16:01 17 
37 
DRB1*16:02 20 
Total 54 54 
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Interestingly, the DRB1*16 allele was the most abundant allele in patients. The high 
risk alleles type such as DRB1*01 and DRB1*10 were found only is 3 RA samples. 
3.3 Sequence of Shared Epitope and Other Regions of HLA-DRB1 Associated   
       with RA 
 The shared epitope region, which forms amino acids 70-74 of the mature 
protein, is by far regarded as the strongest indicator of an association between HLA 
genes and RA (Ruyssen-Witrand et al., 2015). From the sequence alignment and 
translation from this, the SE region and the corresponding amino acids representing 
this region are provided in Table 8 for controls and a summary of unique SE sequences 
observed is provided in Table 9. SE sequences for patients are provided in Table 10 
and the corresponding summary in Table 11. Outside the SE regions, variations at 
positions 11 and 13 of the mature HLA-DRB1 protein are also known to be associated 
with RA. The corresponding sequences observed in these samples are also listed in the 
tables mentioned above. The sequence DRRAA was the most common SE in controls 
(34/43) as well as patients (35/54). The QARAA was also present in a number of 
patient samples (10/54), while the other observed SE sequences had low incidence in 
these samples. 
Table 8: HLA-DRB1 Shared epitope and positions 11/13 in control samples. 
Sample Shared Epitope (DNA) 
SE(70-
74) 
Amino 
acids 
Codons 11-13 (DNA) 
Amino 
acids  
11-13 
C1 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C2 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C3 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C4 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C5 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
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Table 8: HLA-DRB1 Shared epitope and positions 11/13 in control samples. 
(Continued) 
Sample Shared Epitope (DNA) 
SE(70-74) 
Amino 
acids 
Codons 11-13 
(DNA) 
Amino 
acids  
11-13 
C6 CACGGGCGCGCCGCG HGRAA CCTAAGAGG P-R 
C7 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C8 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C9 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C10 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C11 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C12 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C13 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C14 GACGAGCGGGCCGCG DERAA NOT AVAILABLE  
C15 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C16 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C17 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C18 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C19 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C20 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C21 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C22 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C23 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C24 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C25 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C26 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C27 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C28 GACAGGCGCGCCGCG DRRAA CCTAAGAAG P-K 
C29 GACAAGCCCGCCCCG DKPAP CCTAAGAGG P-R 
C30 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C31 CACGCGCGCGCCGCG HARAA CCTAAGAGG P-R 
C32 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C33 CAGGCGCGGGCCGCG QARAA CCTAAGAGG P-R 
C34 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C35 CAGGCGCGGGCCGCG QARAA CCTAAGAGG P-R 
C36 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C37 CACGGGCGCGCCGCG HGRAA CCTAAGAAG P-R 
C38 GACGGGCGCGCCGCG DGRAA CCTAAGAGG P-R 
C39 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C40 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C41 CACGAGCGGGCCGCG HERAA CCTAAGAGG P-R 
C42 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
C43 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
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Table 9: Count of shared epitope sequence in control samples. 
Shared epitope sequence Count 
DRRAA 34 
HGRAA 2 
DERAA 1 
DKPAP 1 
HARAA 1 
QARAA 2 
DGRAA 1 
HERAA 1 
Total 43 
 
The low risk SE sequence DRRAA is more frequent in control samples which 
is related to HLA-DRB1*16 allele type. The amino acid at position 11 and 13 did not 
the high risk variant in the control samples.  
Table 10: HLA-DRB1 Shared epitope and positions 11/13 in RA samples. 
Sample Shared Epitope (DNA) 
SE(70-74) 
Amino acids 
Codons 11-13 
(DNA) 
Amino 
acids 
11-13 
RA1 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA2 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA3 CACGGGCGCGCCGCG HGRAA CCTAAGAGG P-R 
RA4 CAGGCGCGGGCCGCG QARAA CCTAAGAGG P-R 
RA5 CAGGCGCGGGCCGCG QARAA CCTAAGAGG P-R 
RA6 CGGAGGCGTGCCGCG RRRAA GTTAAGTTT V-F 
RA7 CACGCGCGCGCCGCG HARAA CCTAAGAGG P-R 
RA8 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA9 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA10 CACGCGCGCGCCGCG HARAA CCTAAGAGG P-R 
RA11 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA12 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA13 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA14 CAGGCGCGGGCCGCG QARAA CCTAAGAGG P-R 
RA15 CAGAGGCGGGCCGCG QRRAA CTTAAGTTT L-F 
RA16 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA17 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA18 CAGAGGCGGGCCGCG QRRAA CTTAGGTTT L-F 
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Table 10: HLA-DRB1 Shared epitope and positions 11/13 in RA samples. 
(Continued) 
Sample Shared Epitope (DNA) 
SE(70-74) 
Amino acids 
Codons 11-13 
(DNA) 
Amino 
acids 
11-13 
RA19 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA20 CAGGCGCGGGCCGCG QARAA CCTAAGAGG P-R 
RA21 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA22 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA23 CACGCGCGCGCCGCG HARAA CCTAAGAGG P-R 
RA24 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA25 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA26 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA27 CAGGCGCGGGCCGCG QARAA CCTAAGAGG P-R 
RA28 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA29 CACGAGCGGGCCGCG HERAA CCTAAGAGG P-R 
RA30 CAGGCGCGGGCCGCG QARAA CCTAAGAGG P-R 
RA31 CAGGCGCGGGCCGCG QARAA CCTAAGAGG P-R 
RA32 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA33 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA34 CAGGCGCGGGCCGCG QARAA CCTAAGAGG P-R 
RA35 GACAGGCGCGCCGC DRRAA CCTAAGAGG P-R 
RA36 CAGGCGCGGGCCGC QARAA CCTAAGAGG P-R 
RA37 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA38 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA39 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA40 CACGCGCGGGCCGCG HARAA CCTAAGAGG P-R 
RA41 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA42 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA43 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA44 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA45 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA46 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA47 CAGGCGCGGGCCGCG QARAA CCTAAGAGG P-R 
RA48 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA49 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA50 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA51 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA52 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA53 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
RA54 GACAGGCGCGCCGCG DRRAA CCTAAGAGG P-R 
 
 
 
 
54 
 
 
 
 
Table 11: Count of shared epitope in RA samples. 
 
Shared epitope sequence Count 
DRRAA 35 
HGRAA 1 
QARAA 10 
RRRAA 1 
HARAA 4 
QRRAA 2 
HERAA 1 
Total 54 
 
In RA patients, the high risk SE sequences (RRRAA and QRRAA) were 
observed only in the 3 sample out of 54 which belong to the high risk allele type of 
HLA-DRB1 mentioned in Tables 6 and 7.  
3.4 HLA-A Allele Typing 
Unlike HLA-DRB1, a class II gene, allele typing of a HLA class I gene like 
HLA-A is normally performed with the sequence of exon 2 and 3. For this, the 
combined sequence of exon 2 and 3 of HLA-A was used as the input to perform a 
BLAST search against the HLA allele database. BLAST results were interpreted to 
identify the HLA-A allele type for control and patient samples. Allele types 
determined for controls are listed in Table 12 and a summary of the incidence of each 
allele type is provided in Table 13, while the allele types determined for patients are 
listed in Table 14 and the corresponding summary in Table 15. At 2-digit resolution 
the allele HLA-A*11 was the most common allele type observed in the controls 
(14/44) and patients (21/38). Specifically, the HLA-A*11:88 had the highest incidence 
of 15/38 among patients.  
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Table 12: HLA-A allele type in control samples. 
Sample Allele 
C1 A*31:110 
C2 A*31:08 
C3 A*31:10 
C4 A*11:88 
C5 A*34:03 
C6 A*11:40 
C7 A*11:88 
C8 A*32:15 
C9 A*32:01 
C10 A*33:119 
C11 A*01:244 
C12 A*26:70 
C13 A*03:10/A*33:150/A*68:129 
C14 A*11:40 
C15 A*03:22 
C16 A*29:02/A*33:18 
C17 A*01:200 
C18 A*11:17 
C19 A*31:111/A*33:9 
C20 A*33:59 
C21 A*33:18 
C22 A*33:13 
C23 A*02:97 
C24 A*30:117 
C25 A*33:85 
C26 A*11:88 
C27 A*30:26 
C28 A*30:09 
C29 A*26:70 
C30 A*03:57 
C31 A*23:70 
C32 A*11:40 
C33 A*11:40 
C34 A*26:172 
C35 A*03:78 
C36 A*11:26 
C37 A*11:99 
C38 A*03:343 
C39 A*03:343 
C40 A*01:136 
C41 A*11:33 
C42 A*11:199 
C43 A*11:99 
C44 A*11:99 
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Table 13: Summary of HLA-A allele types in control samples at 4- and 2-digit 
resolutions. 
Allele Count (4 digits) Count (2 digits) 
A*01:136 1 
3 A*01:200 1 
A*01:244 1 
A*02:97 1 1 
A*03:22 1 
5 
A*03:343 2 
A*03:57 1 
A*03:78 1 
A*11:17 1 
14 
A*11:26 1 
A*11:33 1 
A*11:40 4 
A*11:88 3 
A*11:99 3 
A*11:199 1 
A*23:70 1 1 
A*26:70 2 
3 
A*26:172 1 
A*30:09 1 
3 A*30:26 1 
A*30:117 1 
A*31:08 1 
3 A*31:10 1 
A*31:110 1 
A*32:01 1 
2 
A*32:15 1 
A*33:13 1 
5 
A*33:18 1 
A*33:59 1 
A*33:85 1 
A*33:119 1 1 
A*34:03 1 1 
A*03:10/A*33:150/A*68:129 1 1 
A*29:02/A*33:18 1 1 
A*31:111/A*33:9 1 1 
Total 44 44 
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Table 14: HLA-A allele type in RA samples. 
Sample Allele 
RA1 A*03:89 
RA2 A*11:88 
RA3 A*11:88 
RA4 A*11:88 
RA5 A*01:136 
RA6 A*11:88 
RA7 A*11:88 
RA8 A*11:88 
RA9 A*11:40 
RA10 A*11:88 
RA11 A*11:88 
RA12 A*03:56 
RA13 A*74:34 
RA14 A*74:34 
RA15 A*31:21 
RA16 A*03:280 
RA17 A*24:87 
RA18 A*26:19 
RA19 A*11:88 
RA20 A*01:192 
RA21 A*74:34 
RA22 A*11:88 
RA23 A*11:88 
RA24 A*11:199 
RA25 A*11:178 
RA26 A*11:40 
RA27 A*74:10 
RA28 A*11:88 
RA29 A*30:12 
RA30 A*11:99 
RA31 A*11:88 
RA32 A*11:88 
RA33 A*11:199 
RA34 A*11:88 
RA35 A*31:79 
RA36 A*03:267 
RA37 A*03:72 
RA38 A*01:192 
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Table 15: Summary of HLA-A allele types in RA samples at 4- and 2-digit 
resolutions. 
Allele Count (4 digits) Count (2 digits) 
A*01:136 1 
3 
A*01:192 2 
A*03:267 1 
5 
A*03:280 1 
A*03:56 1 
A*03:72 1 
A*03:89 1 
A*11:178 1 
21 
A*11:199 2 
A*11:40 2 
A*11:88 15 
A*11:99 1 
A*24:87 1 1 
A*26:19 1 1 
A*30:12 1 1 
A*31:21 1 
2 
A*31:79 1 
A*74:10 1 
4 
A*74:34 3 
Total 38 38 
3.5 Amino Acid Position in HLA-A Associated with RA 
In HLA-A, an asparagine (N) at position 77 in the binding groove of the mature 
protein is known to carry a high RA risk while the wild type is an aspartic acid (D) 
(Han et al., 2014). Hence, codon 77 and the translated amino acid at this position were 
determined for all samples. The amino acid at position 77 for control samples are listed 
in Table 16 and patient samples in Table 17. A summary of the observed amino acids 
at this position in patients and controls are provided in Table 18.  
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Table 16: HLA-A amino acid at position 77 in control samples. 
Sample Amino acid 
C1 N/D 
C2 N 
C3 N 
C4 N 
C5 D 
C6 N 
C7 D 
C8 N/D 
C9 S 
C10 D 
C11 N 
C12 N 
C13 E 
C14 N/D 
C15 D 
C16 N 
C17 N 
C18 N/D 
C19 D 
C20 D 
C21 N/D 
C22 N/D 
C23 D 
C24 N 
C25 D 
C26 D 
C27 D 
C28 N 
C29 N/D 
C30 N 
C31 N 
C32 N 
C33 N/D 
C34 N/D 
C35 D 
60 
 
 
 
 
Table 16: HLA-A amino acid at position 77 in control samples (Continued). 
Sample Amino acid 
C36 D 
C37 N 
C38 D 
C39 D 
C40 N 
C41 N/D 
C42 N/D 
C43 N 
C44 N 
 
Table17: HLA-A amino acid at position 77 in RA samples. 
Sample Amino acid 
RA1 D 
RA2 N 
RA3 N 
RA4 N 
RA5 N 
RA6 N 
RA7 N 
RA8 N 
RA9 N 
RA10 N 
RA11 N 
RA12 N/D 
RA13 N/D 
RA14 N 
RA15 N 
RA16 N/D 
RA17 N 
RA18 N 
RA19 N 
RA20 N/D 
RA21 N/D 
RA22 N 
RA23 N 
RA24 N/D 
RA25 N 
RA26 N 
RA27 N 
RA28 N 
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Table17: HLA-A amino acid at position 77 in RA samples (Continued). 
Sample Amino acid 
RA29 N 
RA30 N 
RA31 N 
RA32 N 
RA33 N/D 
RA34 N 
RA35 N 
RA36 N/D 
RA37 N 
RA38 N 
Table 18: Summary of HLA-A amino acid at position 77 in all samples. 
Amino acid Count (Control) Count (RA) 
N 17 29 
D 14 1 
N/D 11 8 
Non N/D 2 0 
Total 44 38 
Tables 16-18 shows the presence of the missense mutation at position 77 in 
HLA-A samples where aspartic acid was changed to asparagine. This was observed to 
be more frequent in patients than controls. 
3.6 Other Locations in HLA-A with Higher Incidence in Patient 
Based on the alignment obtained, frequency of variations in controls and 
patients were calculated at all locations in exon 2 and exon 3 of HLA-A. A higher 
incidence of variations was observed in patients at positions 56, where a arginine (R) 
replaces a glycine (G) in the reference, and 76, where a glutamic acid (E) replaces a 
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valine (V). To understand the significance of these, structural models of the wildtype 
(Figure 27A) and mutants Gly56Arg (Figure 27B), Val76Glu (Figure 27C) and 
Asp77Asn (Figure 27D) were generated using molecular modeling. 
   
    
Figure 27: Three-dimensional models of wildtype and mutant HLA-A: (A) wildtype; 
(B) Gly56Arg; (C) Val76Glu and (D) Asp77Asn. 
3.7 Odds Ratio for the Three Observed Positions in HLA-A 
To estimate the significance of the observed variations, Fisher’s exact test 
was performed to compute the odds ratio and significance using R. The computed 
values are shown in Table 19. 
 
A B 
C D 
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Table 19: Variations in HLA-A with higher incidence in RA samples than control 
samples. 
Position Variant 
RA 
(n=38) 
Control 
(n=44) 
Odds Ratio 
(OR) 
p-value  
(Fisher's test) 
77 N 37 28 20.52 0.0001985 
76 E 29 15 6.075 0.0001589 
56 R 20 10 3.712 0.006273 
 
3.8 Phylogenetic Analysis of Sequences 
To understand the evolutionary relationship between samples, phylogenetic 
trees were constructed using all HLA-DRB1 exon 2 sequences (Figure 28) and HLA-
A exon 2+3 sequences (Figure 29) using MEGA 6.  
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Figure 28: Phylogenetic constructed from HLA-DRB1 exon 2 sequences. 
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Figure29: Phylogenetic constructed from all HLA-A exon 2 & 3 sequences. 
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3.9 Principal Component Analysis 
Principal Component Analysis (PCA) of the DNA sequences was performed 
in R using the adegenet package to reduce the dimensionality of the dataset and to 
determine if the patient and control samples would distinctly cluster. PCA plots 
obtained for principal component 1 versus principal component 2 for HLA-DRB1 is 
shown in Figure 30 and HLA-A in Figure 31.  
 
Figure 30: A plot of principal component 1 against component 2 obtained from PCA 
of HLA-DRB1 exon 2 sequences. Red dots represent patient samples and blue dot 
represents control samples. 
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Figure 31: A plot of principal component 1 against component 2 obtained from PCA 
of HLA-A exon 2 and 3 sequences. Red dots represent patient samples and blue dot 
represents control samples. 
3.10 Fixation Index 
Fixation Index (FST) was computed for HLA-DRB1 and HLA-A sequences 
using Arlequin. The obtained FST values were 0.02263 (p-value 0.04985) for HLA-
DRB1 and 0.06811 (p-value 0.00098) for HLA-A.  
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Chapter 4: Discussion 
 
 
RA is a chronic heterogeneous autoimmune disorder of unknown etiology 
resulting in inflammation in the cartilage, synovium, and bone (O'Rielly & Rahman, 
2010). It is the second most predominant autoimmune disorder. Early diagnosis and 
management is important for the notable improvement and favorable outcomes. The 
absence of timely intervention lead to negative impact to patient health together with 
a large societal burden (Kurko et al., 2013). RA usually appears after 30-40 years of 
life and is more common in women which may be related to hormonal factors. RA is 
reported to be present in 0.5-1% of the worldwide (Sangha, 2000; Trier et al., 2018).  
Genetic factors often play a defining role in the pathogenesis of RA. Studies 
have reported that the heritability of RA is from 50-60% (MacGregor et al., 2000). 
There are multiple known loci that are associated with the risk of developing RA 
(Bowes & Barton, 2008). Consequently, various genes have been studied as risk 
factors for RA. Most of these genes are believed to be involved in immune system and 
forms part of the major histocompatibility complex (MHC), known in the humans as 
the Human Leukocyte Antigens (HLA). Importantly, this region is responsible for 
approximately 30% of genetic susceptibility to RA (Bowes & Barton, 2008). 
Specifically, among the HLA genes, HLA-DRB1 alleles are strongly associated with 
RA (Jun et al., 2007; Lee et al., 2008). However, multiple studies have indicated that 
other HLA genes are also linked with RA including HLA-A, HLA-B, and HLA-DPB1 
(Coenen & Gregersen, 2009; Imboden, 2009). Interestingly, various alleles of HLA-
DRB1 which are known to be associated with RA associate with what is known as the 
SE region (Huizinga et al., 2005). This region is encoded by exon 2 of the HLA-DRB1 
gene and corresponds to amino acids 70-74 in the mature protein. It has been 
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established that the acid-base properties of SE amino acid could have impact on the 
interactions of HLA-DRB1SE motif (du Montcel et al., 2005). Alleles that have the 
conserved SE amino acids sequences such as QKRAA, QRRAA, and RRRAA in the 
third hypervariable region of the DRB1 chain between positions 70 to 74 are very 
strongly associated with RA and is often used as a genetic biomarker for RA risk 
association (Gregersen et al., 1987; Morgan et al., 2008). DRB1*04:01,*04:04, 
*04:05, *04:08, *13:03, *01:01, *01:02, *14:02, *14:06, *15:01, *15:02, and 15:03 
are the most studied alleles linked with RA but not all alleles display the same 
magnitude of association (Gonzalez-Gay et al., 2002; Gorman et al., 2004; Imboden, 
2009). SE allele's frequency varies between populations. It has been reported that 
DRB1*04:01 and 04:04 were significantly associated with RA in Caucasian 
populations, whereas Asian and Jewish RA patients were predominantly linked with 
DRB1*04:05 and *01:01 alleles (Barnetche et al., 2008; Okada et al., 2014; Ollier & 
Thomson, 1992). Based on this, the basic hypothesis of this study was that RA in 
Emirati patients could also be associated with the high risk SE sequences. This is the 
first study to our knowledge, to investigate the association of shared epitope with RA 
in Emirati population. For this, 44 control and 54 RA Emirati samples were obtained 
and evaluated from Fujairah Hospital after obtaining informed consent. HLA-DRB1 
exon 2 of each subject was amplified and sequenced by using Sanger sequencing 
method. 
 For the HLA-DRB1 gene, the most prevalent allele in the patient group and 
control group was DRB1*16:02 which is considered as a low risk allele in the context 
of RA. The high risk alleles DRB1*10:01 was found in only one patient and 
DRB1*01:02 was found in 2 patients. Out of 43 control subjects 34 had the amino acid 
sequence DRRAA as the SE, while this SE was observed in 35 of 54 patient samples 
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(Tables 9 & 11). Studies have suggested that the DRRAA sequence which usually 
corresponds to HLA-DRB1*16, *11, and *12 alleles, is a low risk allele and is not 
associated with RA (du Montcel et al., 2005). Moreover, it was reported that amino 
acid at position 70 influences the susceptibility to RA and the presence of aspartic acid 
(D) at this position is believed to provide a protective effect as opposed to glutamine 
(Q) or arginine (R) (Trier et al., 2018). Interestingly, RRRAA is a high risk allele and 
mostly prevalent in Asian population (Mohan et al., 2017; Muazzam et al., 2013). This 
SE was observed in only 1 out of 54 RA patients and was absent in control subjects. 
Together, the high risk SEs QRRAA/RRRAA were observed in only 3 patients. 
Surprisingly, the low risk SEs DRRRA/QARAA/DERAA were observed in 37 of 43 
controls and 45 of 54 patients (Table 9 & 11). The shared epitope hypothesis was 
formulated on the basis of a large body of evidence suggesting that the SE is the most 
significant cause of RA that can be attributed to variations in the HLA genes 
(Holoshitz, 2010). Putting together the data in this study, it appears that the low risk 
SEs predominate both the patient and control samples and high risk SEs have low 
incidence indicating that the HLA-DRB1 SE region is not the major cause of RA in 
this sample of the population. 
Looking outside the SE region of HLA-DRB1, it has been established that 
specific amino acids at positions 11 and 13 could also impart high RA risk. These 
amino acids line the base of the peptide binding groove (Scally et al., 2013). A valine 
or leucine at position 11 (neutral) and/or a histidine at position 13 (basic) have been 
associated with an increased risk of RA (du Montcel et al., 2005; Raychaudhuri et al., 
2012; Reynolds et al., 2014; Scally et al., 2013). Therefore, this region was examined 
in both patient and control samples. However, in the vast majority of patient and 
control samples, a proline was found at position 11 and an arginine at position 13 as 
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shown in Tables 8 & 10, both of which have not been reported to increase the risk of 
RA. However, a leucine or valine was observed in 3 out of 54 patients placing them at 
a high risk of having RA. Nonetheless, very few of the RA cases could be attributed 
to variations in the shared epitope and positions 11 or 13 indicating that HLA-DRB1 
is likely not the major cause for RA in this population. 
Setting HLA-DRB1 aside, among the HLA genes, variations in HLA-A has 
also been shown to impart significant RA risk. A study of European seropositive RA 
patients demonstrated an additional independent RA-risk in HLA-A amino acid at 
position 77. A high risk was associated with asparagine at position 77 of the mature 
protein (Han et al., 2014). Interestingly, this variation was observed to impart 
protection in HIV controls (Morrison et al., 2007).  To assess the association of HLA-
A gene with RA in this population, exon 2 and exon 3 of HLA-A was sequenced to 
identify the allele types and genetic variations in this region. Out of 38 Emirati RA 
patients, 37 had missense mutation at amino acid 77 where aspartic acid was mutated 
into asparagine (D>N) whereas, this variation was present in only 28 healthy controls 
(Table. 18).  This placed it at a significant risk for RA in this population with an OR 
of 20.52 (p-value 0.0001985) (Table 19). Interestingly, two missense variations - 
Val76Glu and Gly56Arg - with an OR of 6.075 (p-value 0.0001589) and 3.712 (p-
value = 0.006273), respectively were also observed in this population (Table. 19). The 
Val76Glu mutation was observed in 29 out 38 RA patients whereas in controls it was 
present in only 15 individuals out of 44. Similarly, variant Gly56Arg was observed in 
20 patients while only 10 controls had this variation. Amino acid 77 is critical to the 
function of HLA-A since it is present in binding groove. The amino acid aspartic acid 
has overall negative charge, while asparagine is a polar amino acid and mostly involve 
hydrogen bonding with other residues. Therefore, this variation could disrupt the 
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binding ability of HLA-A.  Position 76 is adjacent to this in the binding groove. Valine 
is a non-polar amino acid while glutamic acid is negatively charged. Like position 77, 
a hydrophobic to charged amino acid at location 76 is likely to affect the binding 
characteristics of the binding groove. Structural models illustrate the location and 
proximity of this amino acid in the binding groove (Figure 27). Position 56 is located 
near the peptide binding groove of HLA-A (van Deutekom & Keşmir, 2015). A 
Gly>Arg results in a change from a small achiral amino acid to a large charged amino 
acid. This is likely to affect protein flexibility and interactions due to the change in 
size and charge of the amino acid change. While these variations may have a role in 
RA it is also likely that this may increase an individual’s risk towards other comorbid 
conditions. These variations have not been reported in the literature. Hence, further 
studies are required to clearly elucidate the role of these variations.  
Finally, to evaluate if the genetic sequences of patients and controls cluster 
separately into one or more groups, several kinds of analyses were performed. 
Phylogenetic analysis, PCA and fixation index all indicated that patients and controls 
form a homogeneous group and there is no clear clustering at the gene level (Figures 
38-31). Therefore, it appears that variations at specific locations are key to a higher 
risk of RA. 
While this study evaluated two HLA genes that account for the vast majority 
of RA cases, isolated variations in HLA-B and HLA-DPB1, both at position 9, have 
also been linked to RA (Han et al., 2014; S. Raychaudhuri et al., 2012). However, due 
to time and funding limitations, these could not be investigated in this study. Apart 
from the HLA region, a few other genes have also been associated with RA in this 
region (Yamamoto et al., 2015). A detailed evaluation of these regions with either 
conventional Sanger sequencing or Next Generation Sequencing (Chen et al., 2018; 
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Hosomichi et al., 2015) could be employed to get a comprehensive understanding of 
how genetic variations could play a role in RA in this population. Genome wide 
association studies (GWAS) could also be considered using a large sample size to 
elucidate genetic variations associated with RA in this population. 
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Chapter 5: Conclusion 
 
RA is widely attributed to an autoimmune response. Variations in several HLA 
genes are associated with an increased risk for RA. Two specific HLA genes HLA-
DRB1 and HLA-A that account for the vast majority of RA cases associated with the 
HLA region were investigated in this study. The SE hypothesis suggests that specific 
sequences between amino acids 70-74 of the HLA-DRB1 protein is the leading risk 
factor. Furthermore, positions 11 and 13 of this protein were also associated with RA. 
However, this study found extremely low incidence of these high risk variations in the 
samples collected from Fujairah Hospital in the UAE. Asparagine at position 77 of 
HLA-A is another leading RA risk factor. In the samples studied, 37 of 38 patients had 
the asparagine at position 77 suggesting that this variation could be a stronger 
biomarker for RA in this population. To confirm this finding, and to extend it further, 
evaluation of a larger sample of both patient and controls is recommended. 
Furthermore, other HLA and non-HLA genes could also be evaluated to find their 
association with RA in the Emirati population. Genome-wide approaches and the 
impact of the environment may also be necessary to gain a holistic understanding of 
genes, pathways and interactions that impart significant risk of RA in the population 
of UAE.  
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